Podcast Episodes
Back to Search
May 31, 2026 | ASCO 2026: Revolution Medicines Pancreatic Data Called 'Unprecedented'; Ivonescimab 34% OS
RevMed's ASCO pancreatic cancer data earn 'unprecedented' from three major outlets — potential paradigm shift in a historically intractable tumor. Pl…
1 month, 3 weeks ago
May 29, 2026 | Pfizer's $10.5B Innovent Deal Extends China Licensing Wave; BMS Mezigdomide Phase 3
Pfizer and Innovent strike a deal worth up to $10.5B for 12 cancer programs — the sixth mega-licensing deal out of China since last July. BMS wins Ph…
1 month, 3 weeks ago
May 28, 2026 | GSK/Ionis Bepirovirsen Achieves 19% Functional Cure in Hepatitis B
Bepirovirsen hits 19% functional cure rate in Phase 3 chronic HBV trials — a first for a disease affecting 300 million. Plus Spero's 245% surge on te…
1 month, 3 weeks ago
May 20, 2026 | Pfizer's Next-Gen Pneumonia Vaccine Beats Prevnar 20; BMS Deploys Anthropic AI
Pfizer's 25-valent pneumococcal shot shows 8.8x–15x higher antibody levels vs. Prevnar 20 in Phase 2, advancing to Phase 3. BMS deploys Claude across…
2 months ago
May 19, 2026 | Takeda $885M Antitrust Verdict; Bimzelx Beats Skyrizi in PsA Head-to-Head
Takeda hit with $885M pay-for-delay verdict over generic Amitiza delay. UCB's Bimzelx beats AbbVie's Skyrizi 49% vs 38% on ACR50 in PsA head-to-head.…
2 months ago
May 18, 2026 | Regeneron LAG-3 Phase 3 Failure Crashes Stock 11%; Supreme Court Cements IRA
Regeneron's fianlimab misses PFS endpoint in melanoma, erasing ~$8B in market cap. Supreme Court rejects IRA pricing challenges from six pharma compa…
2 months ago
May 15, 2026 | FDA's CDER Chief Høeg Expected to Exit; Tecentriq Wins Bladder Cancer Approval
Three top FDA positions now in temporary hands as CDER's Høeg follows Makary out the door. Roche's Tecentriq wins ctDNA-guided bladder cancer approva…
2 months, 1 week ago
May 14, 2026 | AstraZeneca Imfinzi Phase 3 Win in Bladder Cancer; Gene Therapy Safety Overhang
AstraZeneca's VOLGA trial hits EFS and OS incisplatin-ineligible bladder cancer, putting Imfinzi squarely in Keytruda's lane. Plus: Regenxbio's Duche…
2 months, 1 week ago
May 13, 2026 | BeOne's Beqalzi Wins FDA Approval, Breaking BCL-2 Monopoly; Takeda Cuts 4,500 Jobs
FDA approves Beqalzi (sonrotoclax) for mantle cell lymphoma — the first new BCL-2 inhibitor in a decade, directly challenging AbbVie's Venclexta fran…
2 months, 1 week ago
May 12, 2026 | FDA Commissioner Makary Resigns; BMS-Hengrui $15.2B 13-Asset Alliance
FDA Commissioner Makary resigns; Kyle Diamantas steps in as acting chief amid regulatory upheaval. BMS and Hengrui ink $15.2B alliance across 13 prog…
2 months, 1 week ago